Drug Pipeline

Eplontersen Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
0
Recruiting
2
Phase 3
2
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-11 NCT07608354
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and…		 Primary endpoint(s) modified
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-05-27 NCT07608354 A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and… Phase 2 Not Yet Recruiting
Active Studies by Phase
Phase 3
2
Phase 2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT05667493 An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With… Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) Enrolling by Invitation
NCT06194825 EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction… Transthyretin Amyloid Cardiomyopathy Active, Not Recruiting
Phase 2
NCT07608354 A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and… Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Not Yet Recruiting
Sponsors Running Eplontersen Trials
AstraZeneca (2) Ionis Pharmaceuticals, Inc. (1)
Get alerts when Eplontersen trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free